Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1022)	11/10/1998 6:58:00 PM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Pfizer's Zithromax to Help in Fight Against Blinding Trachoma Bloomberg News November 10, 1998, 6:22 p.m. ET Pfizer's Zithromax to Help in Fight Against Blinding Trachoma New York, Nov. 10 (Bloomberg) -- Pfizer Inc. said it will join the Edna McConnell Clark Foundation in a $66 million program intended to use Pfizer's antibiotic Zithromax to fight blindness caused by trachoma, an infection of the eye. Pfizer already has participated in a study of how its Zithromax can be used to treat trachoma. Widespread in some poor countries, this infection can make the eyelid to turn inward, making the lashes scratch against the eye. Zithromax makes it far easier to treat trachoma, especially in children. The standard therapy has been to apply an antibiotic ointment directly to the eyes twice daily, usually for six weeks. Instead, a single dose of Zithromax can treat the infection. The program is part of a so-called SAFE strategy that uses education and environmental changes as well as the drug. ''The donation of Zithromax along with implementation of the full SAFE strategy is helping us to significantly reduce the number of new trachoma cases in Morocco and save the sight of many of our citizens,'' said Abdelwahed el Fassi, Morocco's Minister of Public Health in a press release. Pfizer and the foundation supported a field test of the program over the past two years in Morocco. More than 10,000 people were treated. Trachoma thrives when people do not have adequate access to clean water. Virtually unknown in the U.S. now, it was a leading reason why some immigrants were turned back during processing at Ellis Island earlier in this century, Pfizer said. The new Pfizer and Clark Foundation program will work in five countries: Morocco, Mali, Ghana, Tanzania and Vietnam. The World Health Organization estimates the disease infects more than 150 million people, with 6 million blind or at risk of blindness. Pfizer, based in New York, rose 5/16 to 108 5/8. Zithromax is a favorite antibiotic of many U.S. doctors. It is often prescribed in a form that lets patients take a full course of the drug over a few days, a means of insuring better compliance. Third-quarter sales of Zithromax rose 46 percent to $193 million. --Kerry Dooley in the Washington newsroom through the Chicago

To: Anthony Wong who wrote (1022)	11/11/1998 11:04:00 AM
From: aknahow	Read Replies (2) \| Respond to of 1722

Eisinger is back, at TSC, after a long absence. He was at the ACR in San Diego and has written super article on super-asprin. Covers MRK, PFE and MTC. This is a must read. A free one month trial is available to thestreet.com. Also, to anyone who does not subscribe to TSC a full year of this daily online publication is cheap as the non e-mail full access can be purchased for about, $70 per year. thestreet.com thestreet.com